Studies

Current Endometriosis Research

Understanding endometriosis requires access to reliable, up-to-date research. This Study Page is for those who want to explore the evidence behind current knowledge. It is a curated, searchable research index for endometriosis-specific publications and ongoing clinical studies, and invites you to visually explore the interrelations between research topics that may not be obvious at first glance.

Do you want to:

Studies you can join

Clinical studies seeking participants

Currently recruiting

Device

ENDOVA: Vagus Nerve Stimulation in Symptomatic Endometriosis

Vienna, Austria (on-site)-2026

MedUni Vienna is recruiting for ENDOVA, a prospective, double-blind, sham-controlled, randomized pilot study evaluating whether gentle auricular vagus nerve stimulation with the VIVO® class IIa medical device can improve quality of life and pain in people with symptomatic endometriosis. Participation lasts approximately 4.5 months and includes 6 weeks of device use, weekly appointments in Vienna during the device phase, and an electronic pain diary throughout the study. Basic criteria include age 18-51, surgically confirmed endometriosis or diagnosis by ultrasound/MRI, menstrual pain or chronic lower abdominal pain, and no current hormonal endometriosis therapy; people with a pacemaker cannot participate.

Device

ELECTRE

Bordeaux, France-2026

A single-center randomized study evaluating the efficacy and tolerability of a transcutaneous electrical nerve stimulation (TENS) device for managing endometriosis-associated pelvic pain. The study compares conventional TENS with microstimulation TENS and is recruiting adult women with endometriosis and/or adenomyosis diagnosed by imaging and/or histology.

Device

EndoSolve

Ireland (remote)-2025

OnaWave Medical is developing a novel, non-invasive and painless method for faster diagnosis of endometriosis through analysis of subtle bioelectric rhythms in the pelvis. Built on research from University of Galway and supported by the European Innovation Council.

Recruitment ended - results pending

Ended
Drug

NOVA – Vipoglanstat (Phase 2)

Europe-March 2026

A randomized, double-blind, placebo-controlled Phase 2 trial by Swedish biotech Gesynta Pharma investigating Vipoglanstat, a non-hormonal and non-opioid compound, for endometriosis-associated pain. Approximately 190 women aged 18–45 are being enrolled across multiple European centers to evaluate efficacy, safety, and optimal dosing.

Ended
Natural Compound

Endogreet

Vienna, Austria-2025

A potential non-hormonal treatment approach using Tigovit, a green tea extract, in a randomized, double-blind, placebo-controlled study at MedUni Vienna. Green tea extract has shown promise in reducing both pain and inflammation around endometriosis lesions.

Ended
Device

IMAGENDO

Australia-2025

Imaging study aiming to reduce endometriosis diagnosis time through improved imaging analysis. Participants needed pelvic MRI or transvaginal ultrasound examinations.

Ended
Natural Compound

ENDOFLEX

Vienna, Austria-2021

A MedUni Vienna study investigating Flexofytol, a curcumin extract preparation, as a potential non-hormonal approach for endometriosis-associated pain. The rationale was based on the inflammatory component of endometriosis symptoms and prior clinical data suggesting anti-inflammatory and antioxidant pain-relief effects of curcumin preparations in osteoarthritis.

1 / 1

Published Endometriosis Research

Browse curated endometriosis publications across various categories. Each entry links back to the original publication source.

1 publication

MechanismsInternational Journal of Molecular Sciences

Comprehensive review concluding that no single theory explains all aspects of endometriosis. Disease development involves multiple interconnected mechanisms: retrograde menstruation, immune dysregulation, hormonal imbalances, stem cell involvement, and epigenetic modifications working simultaneously.

PMID: 36901685

Feb 21, 2023

We use cookies to provide the Service. Learn more in our Terms & Privacy Policy.